CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and can afford the risks. Trading CFDs is high risk and is not suitable for everyone. Refer to our PDS and Target Market Determination. AFSL 513393
Open platformOpen platform

UK's Smith & Nephew misses Q3 revenue estimates, cuts outlook on slower US orthopaedics market

By Reuters News


Overview

  • UK medical technology firm's Q3 revenue grew 3.4% yr/yr but missed analyst expectations

  • Company cut full-year revenue and profit growth guidance due to slower US Orthopaedics

  • $500 mln share buyback on track, with $250 mln completed by end-Q3


Outlook

  • Company now expects full-year underlying revenue growth of around 3%, down from around 4%

  • Company expects full-year trading profit growth of around 4%, with trading profit near $1.25 bln

  • Company sees full-year free cash flow of around $750 mln, with cash conversion near 95%


Result Drivers

  • SPORTS MEDICINE & ADVANCED WOUND DEVICES - Co said double-digit growth in Sports Medicine Joint Repair and strong performance in Advanced Wound Devices drove Q3 results

  • ORTHOPAEDICS PRESSURE - Co said US Orthopaedics, especially Hips and Knees, continued to face weak market conditions, limiting overall growth

  • NEWER PRODUCTS - Co said recent product launches contributed over half of Q3 growth, with several products achieving double-digit growth


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Miss

$1.55 bln

$1.57 bln (6 Analysts)


Analyst Coverage

  • The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 4 "strong buy" or "buy", 13 "hold" and 1 "sell" or "strong sell"

  • The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."

  • Wall Street's median 12-month price target for Smith & Nephew PLC is GBp1,220.00, about 9.2% above its November 3 closing price of GBp1,117.50

  • The stock recently traded at 12 times the next 12-month earnings vs. a P/E of 12 three months ago


Reuters Recommended Reads

  • Nov 2 - Denmark medical devices maker Coloplast's Q4 revenue rises

  • Nov 3 - Germany's Fresenius Medical says Q3 results weighed by China; narrows forecast

  • Nov 3 - AtriCure Q3 revenue beats expectations on strong sales of pain management and appendage devices


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.